Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Main Objective: To Evaluate the Long-term Safety and Efficacy of Using the Netrod-RDN Renal Artery Radiofrequency Ablation System in Treating Patients With Refractory Hypertension and Those With Hypertension Who Are Intolerant to Medication in the Real-world Setting

NCT07273877 is registered in ClinicalTrials.gov with Shanghai Golden Leaf MedTec Co. Ltd as lead sponsor.

NCT NCT07273877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07273877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Main Objective: To Evaluate the Long-term Safety and Efficacy of Using the Netrod-RDN Renal Artery Radiofrequency Ablation System in Treating Patients With Refractory Hypertension and Those With Hypertension Who Are Intolerant to Medication in the Real-world Setting
Lead sponsor
Shanghai Golden Leaf MedTec Co. Ltd
Phase
Observational
Overall status
Enrolling by invitation
Start date
August 7, 2025
Completion date
December 30, 2030
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension